Biovire

BioVire is a pre-clinical stage biotechnology company dedicated to developing novel therapeutics that target latent viral infections, with a primary focus on human cytomegalovirus (HCMV). Founded on pioneering research from the University of Arizona, the company utilizes a proprietary platform to identify viral and host factors critical for the maintenance of and reactivation from viral latency. Their lead programs aim to prevent CMV-related complications in immunocompromised populations, such as transplant recipients, by eliminating the latent viral reservoir. By addressing the root cause of viral recurrence rather than just active replication, BioVire seeks to provide long-term solutions for chronic viral management.